Investigational drug · Phase 3
Investigational varicella vaccine
Not approved by FDA. In 2 industry-sponsored Phase 2 or 3 trials that are active or finished in the last two years, most often for Chickenpox.
Phase 3Last checked: Nov 20, 2026Latest source record: May 29, 2026 (newest trial update)Source: ClinicalTrials.govMethods & limitations
Highest phase
Phase 3
Industry-sponsored trials
Phase 2 and 3 trials
2
2 still active
All registered trials
62
Any phase or sponsor naming "Investigational varicella vaccine"
First trial start
2024
Nov 26, 2024
Sponsors
Lead sponsors of its Phase 2 and 3 trials.
All registered trials by phase
Every ClinicalTrials.gov drug study naming "Investigational varicella vaccine", any sponsor or status.
Conditions studied
As listed on its trial records.
- Chickenpox
Largest trials
Live from ClinicalTrials.gov: studies naming "Investigational varicella vaccine" as an intervention, largest first.
- Protective Effect, Safety and Immunogenicity of Live Attenuated Varicella Vaccine in Anhui ProvinceStatus unknown
Sinovac (Dalian) Vaccine Technology Co., Ltd.Industry
NCT05470855 · 45,400 participants (planned) · Start Jul 6, 2022 · Primary completion Nov 30, 2022
Drug: Live attenuated varicella vaccine · For: Varicella
Sites: Anqing, China; Chuzhou, China; Fuyang, China · 5 sites in all
- Phase III Clinical Trial of Lyophilized Herpes Zoster mRNA Vaccine in Adults Aged 40 Years or AbovePivotal-lookingRecruiting
Suzhou Abogen Biosciences Co., Ltd.Industry
NCT07817108 · 18,000 participants (planned) · Start Jun 27, 2026 · Primary completion Oct 17, 2027
Drug: ABO1108; Placebo · For: Varicella-zoster Virus
Sites: Jinan, China; Nanning, China; Shijiazhuang, China · 4 sites in all
- A Phase III Clinical Trial to Evaluate the Efficacy and Safety of the Live Attenuated Varicella VaccinePivotal-lookingStatus unknown
China National Biotec Group Company LimitedIndustry
NCT05669625 · 12,440 participants · Start Dec 26, 2022 · Primary completion Apr 14, 2024
Drug: Investigational live attenuated varicella vaccine; Placebo of live attenuated varicella vaccine · For: Varicella
Sites: Tongren, China; Hebi, China; Jiaozuo, China · 13 sites in all
- A Blind, Randomized and Controlled Study of Live Attenuated Varicella VaccinesPivotal-lookingCompleted
Sinovac (Dalian) Vaccine Technology Co., Ltd.Industry
NCT02981836 · 5,997 participants · Start Aug 2016 · Primary completion Jun 2017
Drug: Investigational live attenuated varicella vaccine; diluent of lyophilized vaccine · For: Varicella
Sites: Xuchang, China; Zhumadian, China
- Consistency Study of GlaxoSmithKline (GSK) Biologicals' MMR Vaccine (209762) (Priorix) Comparing Immunogenicity and Safety to Merck & Co., Inc.'s MMR Vaccine (M-M-R II), in Children 12 to 15 Months of AgePivotal-lookingCompleted
GlaxoSmithKlineGSK (GSK)
NCT01702428 · 5,016 participants · Start Nov 9, 2012 · Primary completion Nov 25, 2014
Drug: Priorix; M-M-R II and 3 more · For: Rubella; Measles; Mumps
Sites: Dothan, Alabama; Phoenix, Arizona; Fayetteville, Arkansas · 90 sites in all
- Safety Study of ProQuad® rHA in Infants (V221-037)Pivotal-lookingCompleted
Merck Sharp & Dohme LLCMerck & Co. (MRK)
NCT00560755 · 3,388 participants · Start Oct 24, 2007 · Primary completion Nov 24, 2008
Drug: ProQuad® · For: Measles; Mumps; Rubella and 1 more
- Safety of a Quadrivalent Meningococcal Conjugate Vaccine Administered Concomitantly With Routine Pediatric Vaccines in Healthy Infants and ToddlersPivotal-lookingCompleted
Sanofi Pasteur, a Sanofi CompanySanofi (SNY)
NCT03673462 · 2,797 participants · Start Sep 17, 2018 · Primary completion Mar 16, 2023
Drug: Meningococcal polysaccharide (serogroups A,C,Y and W) tetanus toxoid Conjugate vaccine (MenACYW Conjugate vaccine); Meningococcal (Groups A, C, Y and W 135) Oligosaccharide Diphtheria CRM197 Conjugate Vaccine (MENVEO®) and 6 more · For: Healthy Volunteers (Meningococcal Infection)
Sites: Birmingham, Alabama; Dothan, Alabama; Phoenix, Arizona · 69 sites in all
- Safety and Immunogenicity of Live Attenuated Varicella Vaccine in Healthy Population Aged ≥13 Years OldPivotal-lookingCompleted
Shanghai Institute Of Biological ProductsIndustry
NCT05158777 · 2,480 participants · Start Feb 13, 2022 · Primary completion Nov 14, 2022
Drug: Live attenuated varicella vaccines manufactured by Shanghai Institute of Biological Products Co.,Ltd.; Live attenuated varicella vaccines manufactured by Changchun BCHT Biotechnology Co.,Ltd · For: Varicella
Sites: Zhenzhou, China
- Safety and Immunogenicity of Live Attenuated Varicella Vaccine in Healthy Population Aged ≥13 Years OldPivotal-lookingStatus unknown
Sinovac (Dalian) Vaccine Technology Co., Ltd.Industry
NCT05015686 · 2,400 participants (planned) · Start Sep 30, 2021 · Primary completion Feb 9, 2022
Drug: Live attenuated varicella vaccines manufactured by Sinovac (Dalian) Vaccine Technology Co., Ltd; Live attenuated varicella vaccines manufactured by Changchun BCHT Biotechnology Co.,Ltd and 2 more · For: Varicella
Sites: Shangqiu, China
- Co-administration Study of an Investigational Live-Attenuated Respiratory Syncytial Virus Vaccine in Infants and ToddlersPivotal-lookingTerminated
Sanofi Pasteur, a Sanofi CompanySanofi (SNY)
NCT06397768 · 2,226 participants · Start May 13, 2024 · Primary completion Sep 18, 2025
Drug: RSVt vaccine; Diphtheria, tetanus, pertussis, poliomyelitis , Haemophilus influenzae type b, and hepatitis B vaccine and 7 more · For: RSV Immunization
Sites: Birmingham, Alabama; Grand Bay, Alabama; Mobile, Alabama · 72 sites in all
Newest research
PubMed records naming it or its code names, newest first.
No PubMed records name it yet, which is common for early code-named drugs.
Also in development for Chickenpox
- Marketed varicella vaccinePhase 33 trials
GSK · Chickenpox
- MMR vaccinePhase 33 trials
GSK · Chickenpox
Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do. More from GSK.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.